Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 30, 2015 11:33 AM ET

Pharmaceuticals

Company Overview of UPM Pharmaceuticals, Inc.

Company Overview

UPM Pharmaceuticals, Inc. provides drug development and contract manufacturing services to pharmaceutical and biotechnology industries. Its services include formulation evaluation, such as content uniformity evaluation, dissolution testing, stability assessment, in-vitro bioequivalence determination, powder flow determination, compressibility evaluation, disintegration testing, friability testing, and tap density testing; analytical services, including dissolution testing, stability testing, purity testing, impurity identification, particle size determination, compatibility testing, solubility screening, hygroscopicity studies, methods qualification and validation, protein and peptide based ...

501 5th Street

Bristol, TN 37620

United States

Founded in 1997

Phone:

423-989-7057

Key Executives for UPM Pharmaceuticals, Inc.

Chairman of the Board and Chief Executive Officer
Age: 61
President and Chief Operating Officer
Age: 59
Executive Director of Technical Services
Vice President of Human Resources and General Counsel
Vice President of Contracting & Drug Development Services
Compensation as of Fiscal Year 2014.

UPM Pharmaceuticals, Inc. Key Developments

UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets

UPM Pharmaceuticals has reached an agreement with Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has submitted an NDA intending for Flibanserin to be the first drug approved to treat hypoactive sexual desire disorder (HSDD), the most common form of female sexual dysfunction. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee.

UPM Pharmaceuticals Reaches Agreement with BioPharmX, Inc. to Commercially Manufacture Solid Dose Iodine Supplement Tablets for Consumer Products Sector

UPM Pharmaceuticals reached an agreement with BioPharmX, Inc. to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.

Similar Private Companies By Industry

Company Name Region
Wilshire Pharmaceuticals, Inc. United States
Amylin Ohio LLC United States
Aquavit Pharmaceuticals, Inc. United States
Bayer Corporation United States
Pharmaderm, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UPM Pharmaceuticals, Inc., please visit www.upm-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.